Comparative agreement of LJ and MGIT-based DST methods.

<p>* for cultures, on which DST results were available from both methods; 11 MGIT and 9 LJ subcultures were contaminated across all four drugs.</p

Comparison of molecular methods with MGIT culture results for isoniazid and rifampin resistance.

<p><b>MA-macroarray method; Hain - GenoType® MTBDR<i>plus</i> method (Hain Lifesciences GmbH, Germany).</b></p><p></p><p>Where R-resistant and S-sensitive, 1 – by the test method (Hain or Macroarray), 2 – by the reference method (MGIT).</p

Comparison of molecular methods with LJ culture results for isoniazid and rifampin resistance.

<p><b>MA-macroarray method; Hain - GenoType® MTBDR<i>plus</i> method (Hain Lifesciences GmbH, Germany).</b></p><p></p><p>Where R-resistant and S-sensitive, 1 – by the test method (Hain or Macroarray), 2 – by the reference method (LJ).</p

Phenotypic first-line DST comparing LJ and MGIT methodology.^*

*<p>DST was set up one culture per patient; contaminated and undetermined results excluded</p

Mycobacterial speciation of cultures isolated from sputum specimens.

<p>Mycobacterial speciation of cultures isolated from sputum specimens.</p

MGIT and LJ culture positive sputum specimens by microscopy result (MTC only)^*.

*<p>specimens for which both MGIT and LJ results available</p

Comparison of overall costs for primary screening, first line DST testing per specimen screened for MGIT, LJ and molecular identification (Macroarray) tests (US dollar).

*<p>includes specimen transportation costs.</p><p><b>≠</b> Macroarray steps include all steps from DNA extraction to reading/reporting of the results.</p><p>Int'L – international prices.</p><p>NA – not applicable.</p

Time (days) to culture and DST results for mycobacterial cultures.

<p>Time (days) to culture and DST results for mycobacterial cultures.</p